All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the ALL Hub spoke to Aaron Logan, UCSF, San Francisco, US. We asked, How are transplant options evolving for patients with acute lymphoblastic leukemia (ALL)?
How are transplant options evolving for patients with ALL?
Logan begins by highlighting that increased use of alternative donors, especially haploid donors, has allowed transplants for people who wouldn't have had one previously. He goes on to outline improvements in criteria to identify patients that would benefit from transplant e.g. MRD positivity or high risk genetic lesions. Finally, he discusses advances in bridging therapies such as lintuzumab and the evolution of CAR T-cell therapy.
When should we consider allo-HSCT in a patient with ALL? And when not?
During the 3rd Annual Meeting of the International Academy for Clinical Hematology (IACH), the ALL Hub spoke to Sebastian Giebel, Maria Sklodowska-Curie National Research...
What is new in CAR T-cell therapy for ALL?
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, What is new in CAR...
Subscribe to get the best content related to ALL delivered to your inbox